| 郭徽,许斌,庞浇安,等.化瘀消瘤方防治原发性肝癌肝动脉化疗栓塞术后栓塞综合征 40例[J].安徽医药,2026,30(2):382-387. |
| 化瘀消瘤方防治原发性肝癌肝动脉化疗栓塞术后栓塞综合征 40例 |
| Clinical study on the prevention and treatment of embolism syndrome after TACE for primary liver cancer with Huayu Xiaoliu recipe |
| |
| DOI：10.3969/j.issn.1009-6469.2026.02.032 |
| 中文关键词: 原发性肝癌 栓塞后综合征 肝动脉化疗栓塞 化瘀消瘤方 |
| 英文关键词: Primary hepatocellular carcinoma Post-embolization syndrome Transcatheter arterial chemoembolization Huayu Xiaoliu prescription |
| 基金项目:广西自然科学基金( 2020GXNSFAA238012)；广西中医药适宜技术开发与推广( GZSY20-25)；广西高校中青年教师科研基础能力项目( 2022KY1668)；广西中医药大学校级科研项目(2023MS022)；广西中医药大学研究生教育创新计划项目( YCSY2023035) |
|
| 摘要点击次数: 384 |
| 全文下载次数: 181 |
| 中文摘要: |
| 目的观察和分析化瘀消瘤方对原发性肝癌病人行肝动脉化疗栓塞( TACE)术后降低栓塞综合征的防治作用。方法分析 2018年 1月至 2021年 1月广西中医药大学第一附属医院收治的原发性肝癌 TACE术后栓塞综合征病人 80例，分为对照组和观察组，每组 40例，对照组于 TACE术后给予常规西医基础治疗，观察组则在对照组治疗的基础上加服化瘀消瘤方，连续干预 3个月。比较两组治疗前后肝功能指标［丙氨酸氨基转移酶( ALT)天冬氨酸氨基转移酶( AST)总胆红素( TBil)及 γ-谷氨酰转移酶(GGT)］、血清肿瘤标志物［甲胎蛋白(AFP)、癌胚抗原(CEA)、异、常凝血酶原( DCP)］的表达、水平以及中医证候积分变化，记录临床疾病控制率和不良反应发生情况，并进行 3年随访，分析两组病人的远期疗效。结果两组病人治疗后各项肝功能指标( ALT、AST、TBil、GGT)、血清肿瘤标志物( AFP、CEA、DCP)、中医证候评分(胁痛、痞块、胸闷、乏力、食少纳呆)均低于本组治疗前，且治疗后观察组积分低于对照组，但仅有胁痛、痞块、胸闷等评分，差异有统计学意义( P<0.05)。观察组疾病控制率为 92.5%，对照组为 75.0%，观察组疾病控制率优于对照组，差异有统计学意义( P<0.05)。观察两组病人术后临床远期疗效发现，观察组肿瘤复发率 5.0%明显低于对照组的 20.0%，差异有统计学意义(P<0.05)。两组病人治疗过程中不良反应发生情况，观察组总发生率为 7.5%，对照组为 27.5%，差异有统计学意义( P<0.05)。结论化瘀消瘤方对原发性肝癌 TACE术后栓塞综合征有较好的防治作用，可减轻化疗后的不良反应，提高临床治疗的有效性，改善肝功能，并且安全性较好，具有推广价值。 |
| 英文摘要: |
| Objective To observe and analyze the preventive and therapeutic effect of Huayu Xiaoliu recipe on reducing embolism syndrome in patients with primary liver cancer after transcatheter arterial chemoembolization (TACE).Methods Eighty patients withembolism syndrome after TACE for primary liver cancer treated in the First Affiliated Hospital of Guangxi University of Traditional Chi-nese Medicine from January 2018 to January 2021 were analyzed. They were divided into a control group and an observation group,with 40 cases in each group. The control group was given conventional western medicine after TACE. The observation group was givenHuayu Xiaoliu recipe on the basis of the treatment of the control group, and the intervention was continued for 3 months. The liver func-tion indicators (ALT, AST, TBil, GGT), the expression levels of serum tumor markers (AFP, CEA, DCP) and the changes in TCM syn-drome scores between the two groups of patients before and after treatment were compared, and the clinical disease control rate and oc-currence of adverse reactions were recorded. Patients were followed up for 3 years to analyze the long-term efficacy of the two groups. Results After treatment, various liver function indicators (ALT, AST, TBil, GGT), serum tumor markers (AFP, CEA, DCP), TCM syn-drome scores (chance pain, lumps, chest tightness, fatigue, lack of appetite and appetite) of the two groups of patients were lower com-pared with those of before treatment. The scores of the observation group were lower than those of the control group, except for thescores of hypochondrium pain, lumps, and chest tightness, and the differences were statistically significant (P<0.05).The disease con-trol rate in the observation group was 92.5%, and that in the control group was 75.0%. The disease control rate in the observation groupwas better than that in the control group, and the difference was statistically significant (P<0.05). Observing the long-term clinical effi-cacy of the two groups of patients after surgery, it was found that the tumor recurrence rate in the observation group was significantly lower than that in the control group, and the difference was statistically significant (5.0% vs. 20.0%, P<0.05). Regarding the occurrenceof adverse reactions during the treatment of the two groups of patients, the total incidence rate was 7.5% in the observation group and27.5% in the control group, and the difference was statistically significant (P<0.05).Conclusions Huayu Xiaoliu recipe has a goodpreventive and therapeutic effect on embolism syndrome after TACE for primary liver cancer. It can reduce the adverse reactions afterchemotherapy, improve the effectiveness of clinical treatment, improve liver function, and has good safety. Has promotion value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
